Berenice Ceron-Trujillo
Berenice Ceron-Trujillo has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Edgar Ramírez-Ramírez
Aequitas Medica, Mexico
6 shared publications - Alberto Agustín Palacios-García
Laboratorios Columbia, Mexico
3 shared publications - Coralys Abreu-Rosario
Hospital Angeles Lomas, Mexico
3 shared publications - Jorge Yamamoto
Hospital San Angel Inn Universidad, Mexico
3 shared publications - Juan Carlos Castillo-Salinas
Laboratorios Columbia, Panzacola 62, Villa Coyoacán, Coyoacán 04000, Mexico City, Mexico
3 shared publications - Adrián Rodríguez-Matías
Servicio de Nefrología, Hospital Angeles Metropolitano, Mexico City 06760, Mexico
2 shared publications
Latest Publications
- 24 July 2026
- Published by University of Toronto Press Inc. (UTPress) in Journal of Veterinary Medical Education
Building Endoscopy Skills on a Budget: Practical Low-Cost Simulators for Veterinary Endoscopy Teaching
Flexible gastrointestinal endoscopy in small animal veterinary practice requires psychomotor and visuospatial skills that differ from those used in open surgery. Training opportunities are often limited by reliance on live animals, which raises ethical and logistical challenges, while high-fidelity simulators remain cost-prohibitive for many programs. This creates a gap in accessible, early-stage endoscopy training. This Teaching Tip describes the development and implementation of a set of low-cost, modular simulation models designed to support acquisition of core endoscopic skills in veterinary learners. Two custom-built task trainers were designed for foreign body retrieval and polypectomy, and a biological model incorporated porcine gastrointestinal tissue into a life-size canine dummy to provide realistic anatomical context and haptic feedback. Although the biological model is based on canine anatomy, the technical skills targeted (endoscope navigation, instrument handling, and visuospatial coordination) are not species-specific and are readily transferable across veterinary and human endoscopy contexts. Training was delivered in a clinical skills laboratory using a station-based format with demonstration and supervised practice. The simulators enabled repeated, hands-on practice of key skills, including scope navigation, mucosal visualization, retroflexion, biopsy, and object retrieval, in a controlled, low-risk environment. Informal feedback from learners and faculty indicated high usability and perceived educational value, particularly for early skill acquisition. These low-cost simulation models offer an accessible and practical approach to veterinary endoscopy training, reducing reliance on live animals and expanding opportunities for deliberate practice in resource-limited settings. Future work should focus on formal validation and integration of objective performance assessment.
- 24 July 2026
- Published by University of Toronto Press Inc. (UTPress) in Journal of Veterinary Medical Education
Building Endoscopy Skills on a Budget: Practical Low-Cost Simulators for Veterinary Endoscopy Teaching
Flexible gastrointestinal endoscopy in small animal veterinary practice requires psychomotor and visuospatial skills that differ from those used in open surgery. Training opportunities are often limited by reliance on live animals, which raises ethical and logistical challenges, while high-fidelity simulators remain cost-prohibitive for many programs. This creates a gap in accessible, early-stage endoscopy training. This Teaching Tip describes the development and implementation of a set of low-cost, modular simulation models designed to support acquisition of core endoscopic skills in veterinary learners. Two custom-built task trainers were designed for foreign body retrieval and polypectomy, and a biological model incorporated porcine gastrointestinal tissue into a life-size canine dummy to provide realistic anatomical context and haptic feedback. Although the biological model is based on canine anatomy, the technical skills targeted (endoscope navigation, instrument handling, and visuospatial coordination) are not species-specific and are readily transferable across veterinary and human endoscopy contexts. Training was delivered in a clinical skills laboratory using a station-based format with demonstration and supervised practice. The simulators enabled repeated, hands-on practice of key skills, including scope navigation, mucosal visualization, retroflexion, biopsy, and object retrieval, in a controlled, low-risk environment. Informal feedback from learners and faculty indicated high usability and perceived educational value, particularly for early skill acquisition. These low-cost simulation models offer an accessible and practical approach to veterinary endoscopy training, reducing reliance on live animals and expanding opportunities for deliberate practice in resource-limited settings. Future work should focus on formal validation and integration of objective performance assessment.
- Open Access
Expert Consensus on the Appropriateness of Saccharomyces cerevisiae Hydrolysate in Obesity Management Using the RAND/UCLA Appropriateness Method
Nutraceuticals are bioactive compounds with potential roles in disease prevention and treatment. Their accessibility and affordability have driven growing interest in obesity care. Among them, bioactive hydrolysates derived from Saccharomyces cerevisiae show promise, yet clinical guidelines seldom address their use. We aimed to develop a guidance statement on their appropriateness using the RAND/UCLA consensus method. A multidisciplinary panel of ten experts rated the appropriateness of a bioactive hydrolysate derived from Saccharomyces cerevisiae across clinical scenarios relevant to obesity care, informed by a targeted evidence review and conducted using the two-round RAND/UCLA consensus method, with ratings on a 1–9 scale. The panel deemed the use of the bioactive hydrolysate derived from Saccharomyces cerevisiae, in combination with lifestyle modifications, as an appropriate intervention for managing obesity-related outcomes. This included its use in patients with specific comorbidities, as an adjunct to standard pharmacotherapy, and in a set of selected clinical scenarios. Based on evidence and expert consensus, a bioactive hydrolysate derived from Saccharomyces cerevisiae is appropriate across a range of clinical scenarios within comprehensive obesity care. Further studies should evaluate long-term effectiveness, broader populations and combination regimens.
Open AccessExpert Consensus on the Appropriateness of Saccharomyces cerevisiae Hydrolysate in Obesity Management Using the RAND/UCLA Appropriateness Method
Nutraceuticals are bioactive compounds with potential roles in disease prevention and treatment. Their accessibility and affordability have driven growing interest in obesity care. Among them, bioactive hydrolysates derived from Saccharomyces cerevisiae show promise, yet clinical guidelines seldom address their use. We aimed to develop a guidance statement on their appropriateness using the RAND/UCLA consensus method. A multidisciplinary panel of ten experts rated the appropriateness of a bioactive hydrolysate derived from Saccharomyces cerevisiae across clinical scenarios relevant to obesity care, informed by a targeted evidence review and conducted using the two-round RAND/UCLA consensus method, with ratings on a 1–9 scale. The panel deemed the use of the bioactive hydrolysate derived from Saccharomyces cerevisiae, in combination with lifestyle modifications, as an appropriate intervention for managing obesity-related outcomes. This included its use in patients with specific comorbidities, as an adjunct to standard pharmacotherapy, and in a set of selected clinical scenarios. Based on evidence and expert consensus, a bioactive hydrolysate derived from Saccharomyces cerevisiae is appropriate across a range of clinical scenarios within comprehensive obesity care. Further studies should evaluate long-term effectiveness, broader populations and combination regimens.
- Open Access
- 1 September 2025
- Published by MDPI AG in Preprints.org
Expert Consensus on the Appropriateness of Saccharomyces cerevisiae Hydrolysate in Obesity Management Using the RAND/UCLA Appropriateness Method
Background: Nutraceuticals are bioactive compounds that have shown promise in disease prevention and management. Due to their accessibility and affordability, they have gained increasing interest in obesity management. Some such nutraceuticals are Saccharomyces cerevisiae hydrolysates. Despite this growing interest, clinical practice guidelines rarely address their use, leaving clinicians with limited direction of their usage in routine care. This study aimed to develop a general guidance statement on the appropriateness of a Saccharomyces cerevisiae hydrolysate using a RAND/UCLA consensus process. Methods: A multidisciplinary panel of nine experts was convened to evaluate the appropriateness of a Saccharomyces cerevisiae hydrolysate in various clinical scenarios related to obesity management. Results: The panel deemed the use a Saccharomyces cerevisiae hydrolysate, in combination with lifestyle modifications, as an appropriate intervention for managing obesity-related outcomes. This included its use in patients with specific comorbidities, as an adjunct to standard pharmacotherapy, and in a set of selected clinical scenarios. Conclusions: Combining practitioners' insights with available data, the panel reached consensus that a Saccharomyces cerevisiae hydrolysate represents an appropriate intervention in a range of clinical scenarios for obesity management.
- 1 September 2025
- Published by MDPI AG in Preprints.org
Open AccessExpert Consensus on the Appropriateness of Saccharomyces cerevisiae Hydrolysate in Obesity Management Using the RAND/UCLA Appropriateness Method
Background: Nutraceuticals are bioactive compounds that have shown promise in disease prevention and management. Due to their accessibility and affordability, they have gained increasing interest in obesity management. Some such nutraceuticals are Saccharomyces cerevisiae hydrolysates. Despite this growing interest, clinical practice guidelines rarely address their use, leaving clinicians with limited direction of their usage in routine care. This study aimed to develop a general guidance statement on the appropriateness of a Saccharomyces cerevisiae hydrolysate using a RAND/UCLA consensus process. Methods: A multidisciplinary panel of nine experts was convened to evaluate the appropriateness of a Saccharomyces cerevisiae hydrolysate in various clinical scenarios related to obesity management. Results: The panel deemed the use a Saccharomyces cerevisiae hydrolysate, in combination with lifestyle modifications, as an appropriate intervention for managing obesity-related outcomes. This included its use in patients with specific comorbidities, as an adjunct to standard pharmacotherapy, and in a set of selected clinical scenarios. Conclusions: Combining practitioners' insights with available data, the panel reached consensus that a Saccharomyces cerevisiae hydrolysate represents an appropriate intervention in a range of clinical scenarios for obesity management.
- Open Access
- 7 May 2025
- Published by MDPI AG in Preprints.org
Systematic Review and Meta-Analysis of the Effects of a Polysaccharide-Rich Hydrolysate Derived from Saccharomyces cerevisiae on Body Weight Reduction
Background/Objectives: Obesity is a major public challenge globally, and pharmacological treatments, though effective, face important limitations related to access, cost, and adherence. Nutraceuticals have emerged as potentially safer, more accessible alternatives. A polysaccharide-rich hydrolysate derived from Saccharomyces cerevisiae (Stetikal®, Lipigo®) has shown promise in clincal trials, but no systematic reviews have been conducted. Methods: We conducted a systematic review and meta-analysis following Cochrane protocols and PRISMA guidelines. The study was prospectively registered in PROSPERO (CRD420251024965). We searched Pubmed, SciELO, ClinicalTrials.gov, CENTRAL, and EMBASE (April 2025) for blinded, randomized, placebo-controlled trials evaluating this hydrolysate in overweight or obese adults. Abstract screening, study selection, data extraction, risk of bias assessment (RoB-2), were performed independently by five reviewers. Outcomes included body weight, BMI, abdominal circumference and fat mass. Results: Three eligible studies comprising 273 participants were included. The meta-analysis showed significant reductions in body weight (SMD = -2.35 kg), BMI (SMD = -2.47 kg/m2), abdominal circumference (SMD = -3.15 cm), and fat mass (SMD = -0.76 kg), all favoring the intervention. Heterogeneity was high for most outcomes, except for abdominal circumference (I2 = 0%). Risk of bias was deemed low in all studies. Conclusions: This systematic review and meta-analysis support the clinical efficacy of a polysaccharide -rich hydrolysate derived from Saccharomyces cerevisiae for short-term weight loss and adiposity reduction. While modest, the observed benefits are comparable to those of conventional pharmacological treatments and suggest that this nutraceutical could serve as a cost-effective, accessible complement or alternative for obesity management.
- 7 May 2025
- Published by MDPI AG in Preprints.org
Open AccessSystematic Review and Meta-Analysis of the Effects of a Polysaccharide-Rich Hydrolysate Derived from Saccharomyces cerevisiae on Body Weight Reduction
Background/Objectives: Obesity is a major public challenge globally, and pharmacological treatments, though effective, face important limitations related to access, cost, and adherence. Nutraceuticals have emerged as potentially safer, more accessible alternatives. A polysaccharide-rich hydrolysate derived from Saccharomyces cerevisiae (Stetikal®, Lipigo®) has shown promise in clincal trials, but no systematic reviews have been conducted. Methods: We conducted a systematic review and meta-analysis following Cochrane protocols and PRISMA guidelines. The study was prospectively registered in PROSPERO (CRD420251024965). We searched Pubmed, SciELO, ClinicalTrials.gov, CENTRAL, and EMBASE (April 2025) for blinded, randomized, placebo-controlled trials evaluating this hydrolysate in overweight or obese adults. Abstract screening, study selection, data extraction, risk of bias assessment (RoB-2), were performed independently by five reviewers. Outcomes included body weight, BMI, abdominal circumference and fat mass. Results: Three eligible studies comprising 273 participants were included. The meta-analysis showed significant reductions in body weight (SMD = -2.35 kg), BMI (SMD = -2.47 kg/m2), abdominal circumference (SMD = -3.15 cm), and fat mass (SMD = -0.76 kg), all favoring the intervention. Heterogeneity was high for most outcomes, except for abdominal circumference (I2 = 0%). Risk of bias was deemed low in all studies. Conclusions: This systematic review and meta-analysis support the clinical efficacy of a polysaccharide -rich hydrolysate derived from Saccharomyces cerevisiae for short-term weight loss and adiposity reduction. While modest, the observed benefits are comparable to those of conventional pharmacological treatments and suggest that this nutraceutical could serve as a cost-effective, accessible complement or alternative for obesity management.
- Open Access
Appropriateness of Ketoanalogues of Amino Acids, Calcium Citrate, and Inulin Supplementation for CKD Management: A RAND/UCLA Consensus
Background: Current treatment for chronic kidney disease (CKD) focuses on improving manifestations and delaying progression. Nutritional approaches play a crucial role in CKD management, and various supplements have become available. Ketoanalogues of amino acids (KAs), calcium citrate, and inulin have been proposed as suitable supplements, yet their widespread use has been limited due to insufficient evidence. This study aimed to generate general guidance statements on the appropriateness of these supplements through a RAND/UCLA consensus process. Methods: A RAND/UCLA consensus panel was convened to evaluate the appropriateness of these supplements in different clinical scenarios. In this study, we present a subgroup analysis focusing on a panel of eleven clinical nephrologists from among the experts. Results: Supplementation of low-protein diets (LPDs) and very low-protein diets (VLPDs) with KA was considered appropriate to reduce manifestations and delay CKD outcomes, supplementation with calcium citrate is considered appropriate to reduce CKD manifestations, and supplementation with inulin is considered appropriate to delay CKD outcomes and manage comorbidities. Conclusions: Based on a combination of clinical experience and scientific evidence, the panel reached a consensus that KA supplementation of LPD and VLPD, calcium citrate, and inulin are appropriate in patients with CKD across various scenarios.
Open AccessAppropriateness of Ketoanalogues of Amino Acids, Calcium Citrate, and Inulin Supplementation for CKD Management: A RAND/UCLA Consensus
Background: Current treatment for chronic kidney disease (CKD) focuses on improving manifestations and delaying progression. Nutritional approaches play a crucial role in CKD management, and various supplements have become available. Ketoanalogues of amino acids (KAs), calcium citrate, and inulin have been proposed as suitable supplements, yet their widespread use has been limited due to insufficient evidence. This study aimed to generate general guidance statements on the appropriateness of these supplements through a RAND/UCLA consensus process. Methods: A RAND/UCLA consensus panel was convened to evaluate the appropriateness of these supplements in different clinical scenarios. In this study, we present a subgroup analysis focusing on a panel of eleven clinical nephrologists from among the experts. Results: Supplementation of low-protein diets (LPDs) and very low-protein diets (VLPDs) with KA was considered appropriate to reduce manifestations and delay CKD outcomes, supplementation with calcium citrate is considered appropriate to reduce CKD manifestations, and supplementation with inulin is considered appropriate to delay CKD outcomes and manage comorbidities. Conclusions: Based on a combination of clinical experience and scientific evidence, the panel reached a consensus that KA supplementation of LPD and VLPD, calcium citrate, and inulin are appropriate in patients with CKD across various scenarios.
- Open Access
- 12 August 2024
- Published by MDPI AG in Preprints.org
Appropriateness of Ketoanalogues of Aminoacids, Calcium Citrate, and Inulin Supplementation for CKD Management: A RAND/UCLA Consensus
Background: Current treatment for Chronic Kidney Disease (CKD) focuses on improving manifestations and delaying progression. Nutritional approaches play a crucial role in CKD management, and various supplements have become available. Ketoanalogues of amino acids (KA), calcum citrate, and inulin have been proposed as suitable supplements, yet their widespread use has been limited due to insufficient evidence. This study aimed to generate general guidance statements on the appropriateness of these supplements through a RAND/UCLA consensus process; Methods: A RAND/UCLA consensus panel was convened to evaluate the appropriateness of these supplements in different clinical scenarios. In this study, we present a subgroup analysis focusing on a panel of eleven clinical nephrologists from among the experts; Results: Supplementation of low protein diets (LPD) and very low protein diets (VLPD) with KA was considered appropriate to reduce manifestations and delay CKD outcomes, supplementation with calcium citrate is considered appropriate to reduce CKD manifestations, and supplementation with inulin is considered appropriate to delay CKD outcomes and manage comorbidities; Conclusions: Based on a combination of clinical experience and scientific evidence , the panel reached a consensus that KA supplementation of LPD and VLPD, calcium citrate, and inulin are appropriate in patients with CKD across various scenarios.
- 12 August 2024
- Published by MDPI AG in Preprints.org
Open AccessAppropriateness of Ketoanalogues of Aminoacids, Calcium Citrate, and Inulin Supplementation for CKD Management: A RAND/UCLA Consensus
Background: Current treatment for Chronic Kidney Disease (CKD) focuses on improving manifestations and delaying progression. Nutritional approaches play a crucial role in CKD management, and various supplements have become available. Ketoanalogues of amino acids (KA), calcum citrate, and inulin have been proposed as suitable supplements, yet their widespread use has been limited due to insufficient evidence. This study aimed to generate general guidance statements on the appropriateness of these supplements through a RAND/UCLA consensus process; Methods: A RAND/UCLA consensus panel was convened to evaluate the appropriateness of these supplements in different clinical scenarios. In this study, we present a subgroup analysis focusing on a panel of eleven clinical nephrologists from among the experts; Results: Supplementation of low protein diets (LPD) and very low protein diets (VLPD) with KA was considered appropriate to reduce manifestations and delay CKD outcomes, supplementation with calcium citrate is considered appropriate to reduce CKD manifestations, and supplementation with inulin is considered appropriate to delay CKD outcomes and manage comorbidities; Conclusions: Based on a combination of clinical experience and scientific evidence , the panel reached a consensus that KA supplementation of LPD and VLPD, calcium citrate, and inulin are appropriate in patients with CKD across various scenarios.
- Open Access
- 29 August 2018
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 14 (12) , 2950-2954
Economic burden of varicella complications in two referral centers in Mexico
Varicella-zoster virus causes varicella (chicken-pox), mainly in young children. Most cases are mild but serious complications can occur, resulting in significant morbidity and mortality. The objective of this study was to estimate the cost burden of varicella hospitalizations in two pediatric reference hospitals in Mexico. This retrospective observational study collected data on patients aged <18 years admitted to two third-level referral hospitals in Mexico. Cases were identified from hospital records using International Classification of Diseases Ninth Revision (ICD-9) codes 052 Chickenpox, or Tenth Revision (ICD-10) codes B01 Varicella (chickenpox). Data on demographic and clinical characteristics and resource use were collected from hospital records. Costs for hospital stay and interventions were obtained from the Mexican Institute for Social Security for 2015 and updated to 2017 costs. A total of 172 hospitalized varicella clinically-confirmed cases and 121 varicella- contacts (with epidemiological linkage to a clinically-confirmed case) were included. Thirty eight of the 172 cases (22.0%) experienced complications. There were no deaths. The median duration of hospitalization was 12 days for cases and 23 days for contacts. The median hospitalization cost was MXN 82,572 (USD 4,434) per case, and MXN 89,453 (USD 4,804) per contact. Although considered a mild disease, varicella was associated with a substantial cost burden in two Mexican third-level referral hospitals.
- 29 August 2018
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 14 (12) , 2950-2954
Open AccessEconomic burden of varicella complications in two referral centers in Mexico
Varicella-zoster virus causes varicella (chicken-pox), mainly in young children. Most cases are mild but serious complications can occur, resulting in significant morbidity and mortality. The objective of this study was to estimate the cost burden of varicella hospitalizations in two pediatric reference hospitals in Mexico. This retrospective observational study collected data on patients aged <18 years admitted to two third-level referral hospitals in Mexico. Cases were identified from hospital records using International Classification of Diseases Ninth Revision (ICD-9) codes 052 Chickenpox, or Tenth Revision (ICD-10) codes B01 Varicella (chickenpox). Data on demographic and clinical characteristics and resource use were collected from hospital records. Costs for hospital stay and interventions were obtained from the Mexican Institute for Social Security for 2015 and updated to 2017 costs. A total of 172 hospitalized varicella clinically-confirmed cases and 121 varicella- contacts (with epidemiological linkage to a clinically-confirmed case) were included. Thirty eight of the 172 cases (22.0%) experienced complications. There were no deaths. The median duration of hospitalization was 12 days for cases and 23 days for contacts. The median hospitalization cost was MXN 82,572 (USD 4,434) per case, and MXN 89,453 (USD 4,804) per contact. Although considered a mild disease, varicella was associated with a substantial cost burden in two Mexican third-level referral hospitals.